Literature DB >> 1516253

A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.

A Bolognesi1, P L Tazzari, C Tassi, G Gromo, M Gobbi, F Stirpe.   

Abstract

Immunotoxins were prepared with several single-chain ribosome-inactivating proteins (RIPs type 1) and with the A-chain of ricin linked to the F(ab')2 fragment of sheep anti-mouse IgG. The cytotoxic activity of these conjugates was tested on human lymphocytes pretreated with an anti-CD3 murine MoAb. The immunotoxins inhibited DNA synthesis in phytohaemagglutinin (PHA)-stimulated lymphocytes with IC50S (concentrations causing 50% inhibition) ranging from 8.9 x 10(-13) to 5.7 x 10(-11) M (immunotoxins containing dianthin 32, saporin, pokeweed antiviral protein from seeds (PAP-S), bryodin, momordin, momorcochin, and trichokirin), 1 x 10(-8) M (immunotoxin containing gelonin) and 5 x 10(-9) M (immunotoxin containing ricin A-chain). The immunotoxin containing saporin linked to the anti-mouse IgG F(ab')2 fragment was also highly toxic to human lymphocytes pretreated with anti-CD2, -CD3, -CD5 and -CD45 MoAbs, with IC50S less than or equal to 10(-11) M. Immunotoxins were prepared also with saporin linked to MoAbs against various CD antigens. The immunotoxin prepared with the anti-CD3 antibody had the highest specific cytotoxicity to human lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516253      PMCID: PMC1554454          DOI: 10.1111/j.1365-2249.1992.tb06959.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelonin conjugate.

Authors:  V Singh; M R Sairam; G N Bhargavi; R G Akhras
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

2.  Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.

Authors:  S Ozawa; M Ueda; N Ando; O Abe; S Minoshima; N Shimizu
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

3.  An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.

Authors:  M Till; R D May; J W Uhr; P E Thorpe; E S Vitetta
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

4.  New indirect approach to the therapeutic use of immunotoxins.

Authors:  O Fodstad; G Kvalheim; A Pihl; A Godal; S Funderud
Journal:  J Natl Cancer Inst       Date:  1988-05-18       Impact factor: 13.506

Review 5.  Immunotoxins containing single-chain ribosome-inactivating proteins.

Authors:  J M Lambert; W A Blättler; G D McIntyre; V S Goldmacher; C F Scott
Journal:  Cancer Treat Res       Date:  1988

6.  Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies.

Authors:  P L Tazzari; M Gobbi; A Dinota; A Bontadini; G Grassi; C Cerato; M Cavo; S Pileri; F Caligaris-Cappio; S Tura
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

7.  Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates.

Authors:  S Siena; D A Lappi; M Bregni; A Formosa; S Villa; M Soria; G Bonadonna; A M Gianni
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber.

Authors:  V S Goldmacher; W A Blättler; J M Lambert; G McIntyre; J Stewart
Journal:  Mol Pharmacol       Date:  1989-11       Impact factor: 4.436

9.  Trichokirin, a ribosome-inactivating protein from the seeds of Trichosanthes kirilowii Maximowicz. Purification, partial characterization and use for preparation of immunotoxins.

Authors:  P Casellas; D Dussossoy; A I Falasca; L Barbieri; J C Guillemot; P Ferrara; A Bolognesi; P Cenini; F Stirpe
Journal:  Eur J Biochem       Date:  1988-10-01

10.  An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients.

Authors:  A Dinota; L Barbieri; M Gobbi; P L Tazzari; S Rizzi; A Bontadini; A Bolognesi; S Tura; F Stirpe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  16 in total

1.  Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage.

Authors:  Shihyoung Kim; Rajni Kant Shukla; Eunsoo Kim; Sophie G Cressman; Hannah Yu; Alice Baek; Hyewon Choi; Alan Kim; Amit Sharma; Zhirui Wang; Christene A Huang; John C Reneau; Prosper N Boyaka; Namal P M Liyanage; Sanggu Kim
Journal:  Biomedicines       Date:  2022-05-24

2.  Anti-CD30 immunotoxins with native and recombinant dianthin 30.

Authors:  A Bolognesi; P L Tazzari; G Legname; F Olivieri; D Modena; R Conte; F Stirpe
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

Review 3.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075

Review 4.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

Review 5.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.

Authors:  Letizia Polito; Alice Djemil; Massimo Bortolotti
Journal:  Biomedicines       Date:  2016-06-01

Review 8.  Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.

Authors:  Francesco Giansanti; David J Flavell; Francesco Angelucci; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Toxins (Basel)       Date:  2018-02-13       Impact factor: 4.546

9.  Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

Authors:  R R French; C A Penney; A C Browning; F Stirpe; A J George; M J Glennie
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

Review 10.  Saporin-S6: a useful tool in cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Daniele Mercatelli; Maria Giulia Battelli; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2013-10-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.